Evidence map›Paper›PMID 15007373›Full record

Trial reportThe pharmacogenomics journal2004

The functional mu opioid receptor (OPRM1) Asn40Asp variant predicts short-term response to nicotine replacement therapy in a clinical trial.

C Lerman, E P Wileyto, F Patterson, M Rukstalis, J Audrain-McGovern, S Restine, P G Shields, V Kaufmann, D Redden, N Benowitz and 1 more

Registry-linked trialAbstract readClinical TrialComparative StudyRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in The pharmacogenomics journal, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00326781 (Bio-Behavioral Predictors of the Efficacy of Nicotine Replacement Therapy - Transdisciplinary Tobacco Use Research Center), which is not on this map. Cited by 86 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
86citing papers in PubMed, 7 pooled it
7.8field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00326781 phase4completednot on this map

Bio-Behavioral Predictors of the Efficacy of Nicotine Replacement Therapy - Transdisciplinary Tobacco Use Research Center (TTURC), Project 2

TypeinterventionalSponsorUniversity of PennsylvaniaRan1999 to 2004Enrolled674ConditionsSmokingArmsNicoderm Transdermal Patch, Nicotine Nasal Spray
3 · Its place in the literature

Who cites it

86 citing papers in PubMed, 7 syntheses or guidelines pooled it, 194 citations in OpenAlex.

  1. Pooled it
  2. Interventions for preventing weight gain after smoking cessation.The Cochrane database of systematic reviews · 2021
    Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. CHRNA3 rs1051730 genotype and short-term smoking cessation.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2011
    Pooled it
  7. Pooled it
  8. Trial
  9. Trial
  10. Convergent evidence that choline acetyltransferase gene variation is associated with prospective smoking cessation and nicotine dependence.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2010
    Trial
  11. Identification of pharmacogenetic markers in smoking cessation therapy.American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics · 2008
    Trial
  12. Trial
  13. Trial
  14. Trial
  15. Association of COMT Val108/158Met genotype with smoking cessation in a nicotine replacement therapy randomized trial.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2007
    Trial
  16. The serotonin transporter 5-HTTLPR polymorphism and treatment response to nicotine patch: follow-up of a randomized controlled trial.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2007
    Trial
  17. Trial
  18. Trial
  19. Article
  20. Review

26 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

C LermanDepartment of Psychiatry, Abramson Cancer Center, University of Pennsylvania, Philadelphia, USA. clerman@mail.med.upenn.edu
E P Wileyto
F Patterson
M Rukstalis
J Audrain-McGovern
S Restine
P G Shields
V Kaufmann
D Redden
N Benowitz
W H Berrettini
University of Pennsylvania · USGeorgetown University Medical Center · USUniversity of Alabama at Birmingham · USUniversity of California, San Francisco · US

Funding

TREATMENT STRATEGIES FOR METHODONE NONRESPONDERSP60DA005186 · NIDA · UNIVERSITY OF PENNSYLVANIA · PI O'BRIEN, CHARLES P · 1997 to 2012
$28.1M
ZDV VS ZDV + DDL VS ZDV + DDL + NVP IN ASYMPTOMATIC HIV PATIENTSM01RR000040 · NCRR · UNIVERSITY OF PENNSYLVANIA · PI FITZGERALD, GARRET A · 1985 to 2006
$21.1M
Research Support CoreP30DA012393 · NIDA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ST.HELEN, GIDEON · 1999 to 2024
$17.1M
PHARMACOKINETICS &PHARMACODYNAMICS OF NICOTINER01DA002277 · NIDA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI BENOWITZ, NEAL L · 1985 to 2012
$6.3M
PHARMACOKINETICS AND PHARMACODYNAMICS OF NICOTINER37DA002277 · NIDA · UNIVERSITY OF CALIFORNIA SAN FRANCISCO · PI BENOWITZ, NEAL L · 1993 to 2002
$1.6M
NCI NIH HHS CA078703NCRR NIH HHS M01-RR0040NIDA NIH HHS DA02277NIDA NIH HHS DA12393NIDA NIH HHS P60DA005186PHS HHS P5084718
6 · The paper itself

Abstract

To determine whether the functional mu-opioid receptor (OPRM1) Asn40Asp variant predicts the comparative efficacy of different forms of NRT, we conducted a clinical trial of transdermal nicotine (TN) vs nicotine nasal spray (NS) in 320 smokers of European ancestry. Smokers carrying the OPRM1 Asp40 variant (n=82) were significantly more likely than those homozygous for the Asn40 variant (n=238) to be abstinent at the end of treatment, and reported less mood disturbance and weight gain. The genotype effect on treatment outcome was most pronounced among smokers receiving TN, particularly during the 21 mg dose phase. Smokers who carry the OPRM1 Asp40 variant are likely to have a favorable response to TN and may benefit from extended therapy with the 21 mg dose.

Indexed as

Administration, CutaneousAdministration, IntranasalAdultAsparagineAspartic AcidFemaleFollow-Up StudiesGenetic VariationHumansMaleMiddle AgedNicotinePredictive Value of TestsReceptors, Opioid, muSmokingTime FactorsAsparagineAspartic AcidNicotineOPRM1 protein, humanReceptors, Opioid, mu

Identifiers

PMID15007373
OpenAlexW1966042288

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.